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Abstract
Background: Botanical medicines are increasingly combined with chemotherapeutics as anticancer drug cocktails.
This study aimed to assess the chemotherapeutic potential of an extract of Taxus cuspidata (TC) needles and twigs
produced by artificial cuttage and its co-effects as a cocktail with 5-fluorouracil (5-FU).
Methods: Components of TC extract were identified by HPLC fingerprinting. Cytotoxicity analysis was performed
by MTT assay or ATP assay. Apoptosis studies were analyzed by H & E, PI, TUNEL staining, as well as Annexin V/PI
assay. Cell cycle analysis was performed by flow cytometry. 5-FU concentrations in rat plasma were determined by
HPLC and the pharmacokinetic parameters were estimated using 3p87 software. Synergistic efficacy was subjected
to median effect analysis with the mutually nonexclusive model using Calcusyn1 software. The significance of
differences between values was estimated by using a one-way ANOVA.
Results: TC extract reached inhibition rates of 70-90% in different human cancer cell lines (HL-60, BGC-823, KB, Bel-
7402, and HeLa) but only 5-7% in normal mouse T/B lymphocytes, demonstrating the broad-spectrum anticancer
activity and low toxicity to normal cells of TC extract in vitro. TC extract inhibited cancer cell growth by inducing
apoptosis and G2/M cell cycle arrest. Most interestingly, TC extract and 5-FU, combined as a cocktail, synergistically
inhibited the growth of cancer cells in vitro, with Combination Index values (CI) ranging from 0.90 to 0.26 at
different effect levels from IC50 to IC90 in MCF-7 cells, CI ranging from 0.93 to 0.13 for IC40 to IC90 in PC-3M-1E8
cells, and CI < 1 in A549 cells. In addition, the cocktail had lower cytotoxicity in normal human cell (HEL) than 5-FU
used alone. Furthermore, TC extract did not affect the pharmacokinetics of 5-FU in rats.
Conclusions: The combinational use of the TC extract with 5-FU displays strong cytotoxic synergy in cancer cells
and low cytotoxicity in normal cells. These findings suggest that this cocktail may have a potential role in cancer
treatment.
Background
Cancer is a multifactorial disease that requires a multi-
targeted therapeutic approach [1,2]. Chemotherapy has
undergone a gradual transition from mono-substance
therapy toward multidrug therapy, and drug cocktails
strategy has become widely adopted. Properly formu-
lated drug combinations are believed to enhance
synergy, and interactions of chemical components
within the combination may improve therapeutic effi-
cacy over single drugs [3-6]. Botanical medicines are
generally plentiful, low cost, and relatively non-toxic in
clinical practice, and in many cases plant extracts are
thought to be therapeutically superior to their single iso-
lated constituents [7,8]. Therefore, botanical medicines
are increasingly combined with chemical medicines in
anticancer drug cocktails, especially in countries where
botanical medicines are well-accepted [9,10]. Some stu-
dies have suggested that for cancer treatment, drug
cocktails combining botanical and chemical medicines
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effects and complications [11-13].
Taxus cuspidata (TC), also called Japanese yew, is an
evergreen tree with anticancer and anti-inflammatory
activities [14-16]. While TC is scarce as a natural
resource, artificial cuttage is reproducible and makes TC
needles and twigs constantly available. DaKeSu, a TC
extract of TC needles and twigs produced by artificial
cuttage, has been under preclinical and clinical investi-
gation in China as a botanical medicinal product
[17,18]. Chinese language sources have reported animal-
based and preclinical studies showing DaKeSu activity
against breast, lung, and digestive tract cancers [17,18],
but the anticancer spectrum and mechanism of the
extract have not been studied in detail.
5-Fluorouracil (5-FU) is one of the most commonly
used drugs for treatment of breast, digestive tract, and
other cancers [19-21]. It is often used clinically in com-
bination with other agents such as paclitaxel, docetaxel,
and cisplatin [22-24]. A few studies have shown syner-
gistic effects of combinations of 5-FU with botanical
medicines or components thereof. For example, oroxylin
A, a bioactive Scutellaria baicalensis Georgi flavonoid,
has synergistic effect with 5-FU on HepG2 human hepa-
tocellular carcinoma and on H22 transplanted mice [25].
Chan-Yu-Bao-Yuan-Tang, an herbal medicine formula,
induced apoptosis synergistically with 5-FU in lung and
cervical cancer cells [26]. Though botanical medicines
and 5-FU are both commonly used in clinical practice,
there have been far fewer studies combining 5-FU and
botanical medicines than on 5-FU or botanical medi-
cines alone.
The aim of this paper is to evaluate the efficacy of the
extract of TC needles and twigs produced by artificial
cuttage as a source of useful anticancer agents and the
co-efficacy at the cellular level of a cocktail combining
TC extract and 5-FU. We also assessed whether TC
extract would influence the pharmacokinetics of 5-FU in
animals. These results show the utility for identifying
herb-chemotherapeutic drug combinations.
Methods
Reagents, cell lines, and animals
5-FU (99.9% purity) was purchased from Shanghai Bang-
cheng Chemical Co., Ltd. (Shanghai, China). The TC
extract was kindly provided by China Hongdoushan
T e c h .C o . ,L t d .( H e i l o n g j i a n g ,C h i n a ) .H P L C - g r a d e
methanol and acetonitrile were purchased from Fisher
Scientfic (Fair Lawn, NJ, USA).
The human cancer cell lines, MCF-7 (breast), PG and
A549 (lung), PC-3M-1E8 (prostate), BGC-823 (gastric),
WM451 (melanoma), Bel-7402 (hepatocellular), KB (oral
squamous), HeLa (cervical), and HL-60 (leukemic), and
the normal cells, mouse spleen T lymphocytes (T cells),
mouse spleen B lymphocytes (B cells), and a human
embryonic lung cell line (HEL), were kindly provided by
the Department of Pathology, Peking University Health
Science Center. The cells were maintained in RPMI-
1640 medium supplemented with 10% fetal bovine
serum (Gibco, Carlsbad, CA), 100 IU/ml penicillin and
100 IU/ml streptomycin in 5% CO2 humidified atmo-
sphere at 37°C.
Ten male Sprague-Dawley rats (6-7 weeks old, 200-
250 g) were purchased from Vital River (Beijing, China).
Five rats in the control group received physiological sal-
ine orally (20 ml/kg b.i.d. for 8 days), and the other 5
rats in the TC extract-pretreated group received a sus-
pension of TC extract orally (0.25 g/kg b.i.d. for 8 days).
After the 8-day treatment period, both groups of rats
received 5-FU (48 mg/kg) by intraperitoneal (i.p.) injec-
tion after a 12-h fast. All animals were maintained
according to the international guidelines for care and
use of laboratory animals and all experimental proce-
dures involving animals were approved by the Ethics
Committee of Beijing Normal University (BNU/EC/01/
2011).
Extract identification
For HPLC fingerprinting, TC extract was dissolved in
methanol and filtered through membrane filters (0.45
μm pore size). A Waters HPLC system equipped with a
1525 pump and a 2487 UV detector (Waters, USA) was
used. A C18 column (4.6 mm × 250 mm, 5 μm, Kroma-
sil) was used as the solid phase, the mobile phase con-
sisted of CH3CN-water (50:50, v/v) (A) and CH3CN-
water (15:85, v/v) (B), and the elution gradient profile
was as follows: 0-15 min, 0% A; 15-20 min, 10% A; 20-
40 min, 25% A; 40-60 min, 40% A; 60-80 min, 50% A;
80 min, 100% A. The flow rate was 0.8 ml/min, the col-
umn temperature was room temperature, the injection
volume was kept at 10 μl; the scan wavelength was set
from 190 to 370 nm, and the detection wavelength was
set at 227 nm.
Cell viability assay
The cell viability was evaluated for both cancer and nor-
m a lc e l ll i n e sb yM T Ta s s a yo n9 6 - w e l lp l a t e s[ 2 7 ]o r
ATP assay on 384-well plates as previously described
[28]. For the MTT assay, cells were seeded on 96-well
plates at 4 × 10
4 cells/ml over night. Then cells were
treated with 10 μg/ml TC extract for 72 h. 10 μlo fa5
mg/ml MTT solution was added to each well and the
plate was incubated at 37°C for 4 h. Subsequently, 100
μl0 . 1 %N H 4Cl and 10% dodecyl phenyl sodium sulfo-
nate solution was added to each well, and the plates
were incubated overnight at 37°C. Absorbance was
detected using a Victor
3 V Multilabel reader (PerkinEl-
mer, USA) with the filter set to 570 nm (reference
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Glo
® Luminescent Cell Viability Assay kit (Madison,
WI, USA). Briefly, cells were seeded on 384-well plates
at 2 × 10
4 cells/ml over night. Various concentrations of
single 5-FU, single TC extract or combination (1:1) in
the same volume (0.1, 0.3, 1, 3, 10, 30,100, 300 μg/ml)
were added and the plates were incubated at 37°C for
72 h. The detection protocol included the addition of 10
μl of the working solution of the ATP kit to each well.
The luminescence of each well was measured using a
Victor
3 V Multilabel reader (PerkinElmer, USA).
Histology and immunohistochemistry
Cells were cultured in chamber slides on 6-well plates at
5×1 0
5 cells/ml and allowed to attach overnight, fol-
lowed by treatment with 10 μg/ml TC extract for 24 h.
Cells were washed with phosphate-buffered saline (PBS),
fixed with freshly prepared ice-cold 4% paraformalde-
hyde, and then stained with H & E (St. Louis, MO,
USA). Cells were observed using a Leica DM-RXA
microscope.
Cells were treated with TC extract for 24 h, harvested
by trypsinization, washed twice with PBS, and fixed for
1 h in 1% paraformaldehyde. After RNase treatment, the
cells were adjusted to a density of 1 × 10
6 cells/ml, and
then stained with PI (St. Louis, MO, USA). Immuno-
fluorescent images were acquired using a Leica TCSNT
confocal microscopy.
TUNEL staining was performed using an Apo-Direct
kit (San Diego, USA) according to the manufacturer’s
instructions. Briefly, cells were cultured in chamber
slides on 6-well plates at 5 × 10
5 cells/ml over night.
Then cells were treated with 10 μg/ml TC extract for 24
h. The cells were fixed with 4% paraformaldehyde for 60
min at room temperature, washed 3 times with PBS,
permeabilized with 0.1% Triton X-100 in 0.1% sodium
citrate, and then rinsed with PBS. Cells were stained
with 50 μl TUNEL reaction mixtures at 37°C for 60 min
and washed with PBS. Afterwards, the cells were viewed
using an optical microscope.
Annexin V/PI Assay
Annexin V/PI assay was determined using the Annexin-
V FITC Staining kit (Beijing Biosea Biotechnology Co.,
LTD, China) in combination with propidium iodide,
according to the manufacturer’s instructions. Briefly,
cells were cultured in T25 flasks at a density of 5 × 10
5
cells/ml and allowed to attach overnight, followed by
treatment with 10 μg/ml TC extract for 48 h. Cells were
washed with PBS and incubated with Annexin-V FITC
labeling solution (containing 10 μlA n n e x i n - V -F I T C
labeling reagent in 300 μl incubation buffer) for 15 min
at room temperature and then added 5 μlp r o p i d i u m
iodide solution. Analysis was carried out by flow
cytometry (FACS Calibur, Becton-Dickinson, USA) and
confocal microscopy (Leica, Germany).
Flow cytometry analysis
Cells were cultured in T25 flasks at a density of 5 × 10
6
cells/ml and treated with a series of different concentra-
tions of TC extract (0, 1.67, 4.16, 8.33, 33.33, and 66.67
μg/ml) for 24 h. The cells were harvested by trypsiniza-
tion and washed twice with PBS. For cell cycle and
apoptosis assays, cells were fixed gently in cold 70%
ethanol at 4°C overnight and then re-suspended in PBS
with 0.1 mg/ml RNAse A and 0.1% Triton X-100 and
incubated at 37°C for 30 min. The cell cycle phase and
presence of apoptotic nuclei were determined by stain-
ing with PI. Flow cytometry analyses were performed
using a FACSCalibur instrument and CellQuest software
(Becton Dickinson, USA).
Pharmacokinetic study
Blood samples (0.5 ml) were collected from the retro-
orbital plexus of rats under light ether anaesthesia into
heparinized tubes at 0, 1, 3, 5, 10, 20, 30, 60, 90, 120,
and 240 min after dosing with 5-FU. Blood samples
were centrifuged at 7000 rpm for 5 min. Drug-contain-
ing plasma (200 μl), 200 μl (1 mg/ml) internal standard
(IS) solution, and 600 μl methanol were added to a 2-ml
centrifuge tube for the assay. The sample was shaken
for 1 min using a vortex mixer and then extracted with
ethyl acetate/isopropanol (9:1, v/v). The mixture was
then centrifuged at 3000 rpm for 5 min, and the upper
layer was pipetted into a clean 5-ml centrifuge glass
tube. The sample was then extracted twice more in the
same way. The supernatant was mixed and evaporated
to dryness under nitrogen at 40°C. The dried residues
were reconstituted in 200 μl of methyl cyanide/methanol
(75:25, v/v), vortex-mixed for 10 s, and centrifuged at
3000 rpm for 5 min, and the supernatant was analyzed
by HPLC.
The plasma concentrations of 5-FU were determined
by HPLC. The HPLC system comprised a 1525 pump
and 2487 UV detector (Waters, USA). An Atlantis DC
C18 column (3 μm, 30 mm × 2.1 mm, Waters, USA)
was used. The mobile phase consisted of 10 mM ammo-
nium acetate in water (A) and acetonitrile (B). The gra-
dient program was linearly increased from 10% B to
80% B in the first 2 min, held for 2 min, and then
returned to 10% B. The flow rate was 0.2 ml/min. The
end time of the program was set at 6 min. and the
detection wavelength was 254 nm [29].
Combination index (CI) for determining synergism
additivity or antagonism
The combined effects of TC extract and 5-FU were sub-
jected to median effect analysis with the mutually
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combination index (CI) for determining synergism and
antagonism between the substances was calculated using
Calcusyn1 software (ver 1.1.1, 1996; Biosoft Inc., Cam-
b r i d g e ,U K ) .C I<1 ,C I=1 ,a n dC I>1i n d i c a t e ds y n e r -
gism, additivity, and antagonism, respectively. The results
by ATP assay were analyzed for CI determination.
Statistical analysis
The significance of differences between values was esti-
m a t e db yu s i n gao n e - w a yA N O V A .P<0 . 0 5w a sc o n -
sidered statistically significant.
Results
Component identification of TC extract by HPLC
fingerprinting
Chromatographic fingerprinting is a powerful technol-
ogy for authentication of natural products. The appli-
cation of chromatographic fingerprinting in
component identification of natural products continues
to expand. HPLC fingerprinting of TC extract for qual-
ity control is shown in Figure 1A. The 8 main
compounds of TC extract found in this study are in
agreement with previous reports [9,31-33]. The taxoids
contained high proportions of 7-xyl-10-DAT (9.63%),
9-hydroxyl-13-acetylbaccatin III (9.38%), and baccatin
III (8.32%), moderate amounts of 10-DAT (6.31%) and
taxine A (5.00%), and low amounts of cephalomannine
(2.67%), paclitaxel (2.25%), and 10-DAB III (1.45%).
The structures of these compounds are shown in
Additional file 1.
TC extract inhibits growth of human cancer cells but not
normal cells
To explore the effects of TC extract on human cancer
cell lines and normal cells in vitro, the cytotoxicity of
TC e x t r a c ta t1 0μg/ml for 72 h was assessed by MTT
assays in a panel of human cancer cell lines namely HL-
60, BGC-823, Bel-7402, KB, HeLa and normal mouse T/
B lymphocytes. Figure 1B shows that growth was
strongly inhibited in all cancer cells by 93% for HL-60
cells, 90% for BGC-823 cells, 97% for KB cells, 76% for
Bel-7402 cells, and 80% for HeLa cells. In contrast,
growth of mouse spleen T/B lymphocytes was inhibited
only 7% and 5%, respectively. Therefore, TC extract
showed strong and broad-spectrum anticancer activity
with low toxicity to normal cells.
TC extract induces apoptosis and arrests human cancer
cells at the G2 /M phase
We next performed 3 separate apoptosis assays, H & E,
PI, and TUNEL staining, to determine whether TC
extract inhibited cell growth by inducing apoptosis.
Treatment with 10 μg/ml of TC extract for 24 h pro-
duced significant morphological changes in PC-3M-
1E8 cells compared with control cells. As shown in
Figure 2, TC extract-treated cells displayed cellular
shrinkage and nucleoli ambiguity by H & E staining,
nuclear fragmentation by PI staining, and TUNEL-
positive staining, all typical characteristics of apoptosis,
compared with control cells. Similar effects were seen
in PG and WM451 cells (data not shown). These
results demonstrated that TC extract inhibited cell
growth by inducing apoptosis.
To further measure percentage distribution of TC
extract-induced apoptotic and necrotic human cancer
cells, Annexin V/PI assay was used. Figure 3A shows
specific percentage distributions of PC-3M-1E8 cells as
obtained by flow cytometry. Moreover, confocal micro-
scopy analysis (Figure 3B) demonstrated that significant
apoptosis occured in TC extract-treated PC-3M-1E8
cells as depicted by strong reaction of these cells with
the Annexin V antibody (green) compared to control
cells. Some propidium iodide staining (red) was also
noted in the cells, indicating very late stage apoptosis or
necrosis.
Figure 1 Chemical composition and cytotoxic activity of TC
extract. (A) Peaks: 1, taxine A (5.00%); 2, 10-DAB III (1.45%); 3, 9-
hydroxyl-13-acetylbaccatin III (9.38%); 4, 7-xyl-10-DAT (9.63%); 5,
baccatin III (8.32%); 6, 10-DAT (6.31%); 7, cephalomannine (2.67%); 8,
paclitaxel (2.25%). (B) Differences in TC extract cytotoxicity in 5
human cancer cell lines and normal mouse spleen B and T
lymphocytes. The cell growth inhibition was quantified by the MTT
assay. Cells were treated with 10 μg/ml TC extract for 72 h. The data
shown are from 3 independent experiments.
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by flow cytometry in PC-3M-1E8 cells treated with dif-
ferent concentrations of TC extract for 24 h. As shown
in Figure 4, the cell population in sub-G1 (APO in Fig-
ure 4) gradually increased with TC extract treatment in
a dose-dependent manner, indicating increasing degrees
of apoptosis triggered by the extract. As shown in Figure
4 and Table 1, we also observed gradual dose-dependent
decreases in the G0/G1 phase population (23%-6%) as
compared with a negative control (36%) and increases in
the G2/M phase population (64%-84%) as compared
with a negative control (50%) with increasing concentra-
tions of TC extract, indicating that the cell cycle was
arrested at the G2/M phase. TC extract had similar
effects in PG and WM451 cells (data not shown).
Combination of 5-FU and TC extract produced synergistic
effects on human cancer cells with lower cytotoxicity in
normal cells than 5-FU alone
In order to investigate the anticancer activity of a cock-
tail containing TC extract and 5-FU, cytotoxic studies
were performed in cancerous (A549, PC-3M-1E8, and
MCF-7) and normal (HEL) human cell lines. As shown
in Figure 5, the viability levels of all cell lines decreased
in a dose-dependent manner with increasing doses of
different treatments. The survival of PC-3M-1E8 cells
decreased from 84% to 17% with increasing doses (0.1-
300 μg/ml) of TC extract, from 77% to 14% with
increasing dose (0.1-300 μg/ml) of the 5-FU, and from
67% to 3% with the combination. In addition, TC extract
concentrations above 10 μg/ml significantly enhanced
the inhibitory effects of 5-FU at the same concentrations
(Figure 5C). The same tendency was observed in A549
and MCF-7 cells, where the changes in cell survival
levels with cocktail treatment were statistically signifi-
cant compared with 5-FU treatment alone (Figure 5A
and 5B). Furthermore, the combination of 5-FU and TC
extract showed not only no significant inhibition of HEL
cell growth compared with the individual treatments,
even at a concentration of 100 μg/ml, but also lower
cytotoxicity than 5-FU alone (Figure 5D).
To determine whether the combined effects of the
extract and 5-FU were synergistic, the CI value was cal-
culated where CI < 1, = 1, and > 1 represent synergism,
additive effect, and antagonism, respectively. The CI-fa
curve shown in Figure 6 indicates that the 5-FU and the
TC extract combination yielded synergistic effects with
CI values ranging from 0.90 to 0.26 at different effect
levels from IC50 to IC90 in MCF-7 cells (Figure 6B),
Figure 2 Apoptosis detected by hematoxylin and eosin (H & E),
propidium iodide (PI), and TUNEL staining. PC-3M-1E8 cells were
treated with 10 μg/ml TC extract for 24 h. Cells were processed for
H & E staining (top panel), PI staining (middle panel) and TUNEL
reaction (bottom panel). Apoptotic cells showed condensed and
fragmented nuclei and positive TUNEL reaction. The H & E and
TUNEL staining were observed by optical microscopy (magnification,
× 200). The results of PI analysis were observed by a confocal
microscopy. Scale line = 20 μm.
Figure 3 Apoptotic percentage distribution and observation by
Annexin V/PI assay. PC-3M-1E8 cells were treated with 10 μg/ml
TC extract for 48 h and stained with annexin V-FITC antibody (green
staining) and propidium iodide (red staining) and analysed by flow
cytometry (A) and observed using a confocal microscopy (B). Scale
line = 200 μm.
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PC-3M-1E8 cells (Figure 6C), and with CI < 1 in A549
cells (Figure 6A). In contrast, the CI values were always
> 1 in HEL cells (Figure 6D), indicating that the cyto-
toxic effect of the combination in normal cells was
antagonistic. These results showed that the cytotoxic
effect of the combination of TC extract and 5-FU was
strongly synergistic in human cancer cells but antagonis-
tic in normal cells.
After treated with 5-FU, TC extract or combination
for 72 h, cells images were captured. Each image was
divided into nine equal pieces and one of them was cho-
sen at random then the number of cells was counted. As
shown in Figure 7, compared with the control, the cell
Figure 4 TC extract induced apoptosis in a dose-dependent manner and arrested the cell cycle at G2/M. The sub-DNA apoptotic peak,
G0/G1 peak, and G2/M peak were quantified by flow cytometry after treatment of PC-3M-1E8 cells for 24 h with the following concentrations of
TC extract: 0 μg/ml as a control (A), 1.67 μg/ml (B), 4.16 μg/ml (C), 8.33 μg/ml (D), 33.33 μg/ml (E), and 66.67 μg/ml (F). The cells were stained
with propidium iodide and analysed by flow cytometry.
Table 1 Effect of TC extract on cell cycle distribution in PC-3M-1E8 cells.
TC extract concentration Cell cycle (%)
G0/G1 SG 2/M
0 μg/ml 36.58 ± 1.39 12.49 ± 2.1 50.93 ± 0.93
1.67 μg/ml 23.61 ± 2.01 * 9.59 ± 0.53 * 66.79 ± 1.48 *
4.16 μg/ml 21.09 ± 2.64 * 10.74 ± 0.92 * 68.16 ± 1.86 *
8.33 μg/ml 6.88 ± 0.74 * 9.05 ± 3.33 * 84.07 ± 3.82 *
33.33 μg/ml 6.67 ± 1.54 * 9.71 ± 1.89 * 83.62 ± 3.38 *
66.67 μg/ml 9.46 ± 1.08 * 8.94 ± 1.08 * 81.60 ± 1.95 *
Cell cycle distributions in PC-3M-1E8 cells exposed to TC extract for 24 h, as determined by flow cytometry using propidium iodide staining. Values are mean ±
SEM of 3 experiments. *Significantly different from 0 μg/ml (P < 0.05).
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remarkably after treatment with either TC extract or 5-
FU individually and even further after treatment with
the combination. Nevertheless, the numbers of normal
cells (HEL) were nearly the same, and the cells appeared
healthy. The observations provided additional support to
earlier results that the effect on inhibition of cell growth
of combining TC extract and 5-FU was synergistic in
human cancer cells and antagonistic in normal cells.
TC extract does not affect the pharmacokinetics of 5-FU
in rats
The plasma concentration-time curves for the two
groups after a single i.p. injection of 5-FU were ade-
quately described by a first-order absorption two-com-
partment open model (Figure 8). The pharmacokinetic
parameters were estimated using 3p87 software (Chinese
Pharmacological Society, Beijing, China) and summar-
ized in Table 2. None of the pharmacokinetics para-
meters, including the area under the curve (AUC), the
time to reach the maximum concentration (Tmax), the
maximum concentration (Cmax), or the absorption half-
life (T1/2), showed any significant difference between the
TC extract-pretreated group and the control group.
These results indicates that TC extract did not affect the
pharmacokinetics of 5-FU.
Discussion
In this study, we evaluated the anticancer activity of TC
extract from the needles and twigs of TC,a l o n ea n di n
combination with 5-FU, in vitro. The pharmacokinetic
interactions were further explored in rats. This study
found that TC extract had a strong cytotoxicity to the
10 common human cancer cell lines (BGC-823, PG,
Figure 5 Effect of TC extract and 5-FU on growth of human cancer cell lines and normal cells. Human lung cancer cell line A549 (A),
human breast cancer cell line MCF-7 (B), human prostate cancer cell line PC-3M-1E8 (C), and human embryo lung cell line HEL (D) were
exposed to graded concentrations of TC extract (0.1-300 μg/ml), 5-FU (0.1-300 μg/ml), or the combination for 72 h. The proportion of live cells
was quantified by ATP assay. Each point represents the mean ± S.D. (n = 5), and asterisks indicate significance at P < 0.05, compared with 5-FU
alone.
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PC-3M-1E8), which shown that it had broad-spectrum
anticancer activity in vitro. Besides, it exhibited low toxi-
city to normal cells (mouse splenic T/B lymphocytes
and HEL cells). TC extract inhibited cancer cell growth
by inducing apoptosis and G2/M arrest. Moreover, the
combination of TC extract with 5-FU showed higher
inhibition in a number of human cancer cell lines
(A549, MCF-7, and PC-3M-1E8) and lower cytotoxicity
in normal cells (HEL). In addition, the pharmacokinetics
of 5-FU were not affected by combination with TC
extract. In summary, the effect of combining TC extract
with 5-FU on cell growth inhibition was synergistic in
cancer cells and antagonistic in normal cells. This cock-
tail may therefore have great pharmaceutical potential.
TC is one of the most extensively studied yew species,
and more than 150 taxanes and other compounds have
been reported [34]. Paclitaxel, one component of TC,i s
a popular anticancer drug used in clinical practice to
treat ovarian, breast, and other carcinomas [23,31]. As
an antimitotic agent, it induces cell apoptosis and G2/M
arrest. In our study, HPLC fingerprinting identified 7
main taxoids in addition to paclitaxel in the extract. It
has been reported that some of the taxoids found in the
extract, such as baccatin III, 10-DAB, and cephaloman-
nine, also interact with microtubules and inhibit the
microtubule depolymerization process [14,23]. These
could also inhibit human cancer cell growth as antimito-
tic agents. Therefore, the taxoids in TC extract may
combine to kill human cancer cells by apoptosis and
G2/M arrest.
Kano et al. [35] found that different sequences of
paclitaxel and 5-FU administration had different effica-
cies and toxicities. For example, treatment with pacli-
taxel preceding 5-FU produced additive or synergistic
cytotoxicity in vitro, while simultaneous exposure to
paclitaxel and 5-FU showed mainly subadditive effects
in A549, MCF-7, and WiDr cell lines. This is in contrast
Figure 6 Synergistic antitumor effect of the combination of TC extract and 5-FU in vitro. Combination index (CI) of TC extract with 5-FU in
human lung cancer cell line A549 (A), human breast cancer cell line MCF-7 (B), human prostate cancer cell line PC-3M-1E8 (C), and human
embryo lung cell line HEL (D) was calculated as described. Here, Fraction Affected on the x-axis denotes the proportion of cells affected (e.g., a
Fraction Affected of 0.5 is equivalent to a 50% reduction in cell growth).
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TC and 5-FU had a synergistic anticancer effect in
A549, MCF-7, and PC-3M-1E8 cells. One possible
explanation for this discrepancy is different exposure
times: in the experiment conducted by Kano et al.,t h e
cell lines were exposed to paclitaxel and 5-FU for 24 h,
while we treated for 72 h. The prolonged simultaneous
administration of paclitaxel and 5-FU may restrain the
antagonistic interaction [35]. The difference may also be
due to the other taxoids besides paclitaxel found in TC
extract. It has been reported that simultaneous treat-
ment with docetaxel (an analog of paclitaxel) and 5-FU
resulted in synergistic tumor inhibition in colon carci-
noma xenografts in mice [36].
Interaction of herbals with drugs may also bring about
changes in the pharmacodynamic and pharmacokinetic
properties. Pharmacodynamic interactions may occur
when a conventional drug has either synergistic or
Figure 7 Cytotoxicity in cancerous and normal human cell lines. A549, PC-3M-1E8, MCF-7 and HELwere treated with 10 μg/ml TC extract, 5-
FU or combination for 72 h. Cell images were captured using an Olympus IX51 inverted microscope (magnification × 100).
Figure 8 Plasma concentration-time curves of 5-FU. Blood
samples were analyzed after a single i.p. administration of 48 mg/kg
5-FU to control rats (n = 5; black square) or rats pretreated with TC
extract (1.5 ml/kg for 8 days, per os, n = 5; circle). Each value
represents the mean ± SD of 5 rats.
Table 2 Pharmacokinetic parameters of 5-FU (48 mg/kg)
after a single i.p. injection to control rats (n = 5) or rats
pretreated with TC extract (n = 5).
Parameter Control group Extract-pretreated group
AUC(μg/ml) × min 2317.81 ± 370.12 2864.17 ± 757.25
Tmax(min) 12.53 ± 4.88 16.23 ± 3.79
Cmax(μg/ml) 24.84 ± 7.45 23.32 ± 4.95
V/F(mg/kg)/(μg/ml) 1.77 ± 0.63 1.83 ± 0.41
T1/2(ke)(min) 58.5 ± 19.67 72.6 ± 8.93
T1/2(ka)(min) 3.05 ± 1.82 3.62 ± 1.14
AUC: area under the curve; Tmax: time to reach the maximum concentration;
Cmax: maximum concentration; V/F: apparent volume of distribution; T1/2(ke):
elimination half-life; T1/2(ka): absorption half-life. Values are means ± SD of 5
animals. There was no significant difference between the two groups.
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products. Pharmacokinetic interactions are due to
alteration of absorption, distribution, metabolism, or
elimination of a conventional drug by an herbal product.
The interaction may also increase/decrease the desired
pharmacological effects of the drug [37,38]. For example,
in the clinical trials, the effectiveness of haloperidol was
enhanced when combined with Ginkgo biloba because
of its antioxidant effects [37]. While some herbal pro-
d u c t ss u c ha sg a r l i ca n dS tJ o h n ’s Wort would decrease
the effectiveness of a variety of prescription medications
used to treat some cancers, AIDS, heart disease and
organtransplant patients [38].
The side effects of anticancer agents are a serious pro-
blem in cancer chemotherapy and an effective antican-
cer approach with potent activity and minimal side
effects is highly desirable [15]. It is well known that
some of the side effects of 5-FU are gastrointestinal
such as nausea, vomiting, and myelosuppression. The
association between toxicity and high 5-FU plasma
levels has been reported since the late 1970s [39-41].
Studies have shown that marked elevation and prolonga-
tion of 5-FU levels in the plasma would increase toxicity
of 5-FU [29,40,41]. Pharmacokinetic data can be used to
predict the likelihood of an interaction between the TC
extract and 5-FU. Our results indicated that TC extract
did not affect the pharmacokinetics of 5-FU in rats.
Furthermore, at the cellular level, the cocktail had lower
cytotoxicity in normal cells despite a synergistic antican-
cer effect. Therefore, as a cocktail, combination of 5-FU
with TC extract may show a possibility for enhancing
the efficacy. Still, the exact mechanisms of the effects
need to be further researched in our study, such as
drug-metabolizing enzymes and drug transporter sys-
tems involved.
Lung cancer is the most common cause of cancer-
related death in men and women worldwide. Breast can-
cer is the most prevalent cancer among women and
affects approximately one million women. Prostate can-
cer is one of the most prevalent types of cancer in men.
To expand future possiblity of the cocktail used in
clinic, we chose these common and prevalent cancer
cell lines for the study of combined treatment. And we
found that the cytotoxic effect of the combined TC
extract with 5-FU was strongly synergistic in the three
cancer cell lines (lung cancer - A549, breast cancer-
MCF-7, and prostate cancer - PC-3M-1E8). Other
advantages of TC extract are that TC needles and twigs
can be obtained from artificial cuttage, making the
extract constantly available, easy to prepare and inex-
pensive. In contrast, the extremely small quantity of
paclitaxel in TC [31,42] makes purified paclitaxel rather
expensive, which limits its use, particularly in developing
countries.
Conclusions
In this study, we reported broad-spectrum anticancer
activity of the extract of TC needles and twigs produced
by artificial cuttage. This is the first study to explore a
cocktail of TC extract and 5-FU, which had synergistic
effects on human cancer cells and low cytotoxicity in
normal cells. These results provided important informa-
tion for clinical cancer therapy. Additional, preclinical
and clinical development is certainly needed to explore
the uses of the TC extract-5-FU cocktail for cancer ther-
apy, and the exact mechanism of the synergistic effect
should be further investigated.
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